Clinical trial
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
NCT00276159 · Masonic Cancer Center, University of Minnesota, Other · Terminated
Key facts
| NCT number | NCT00276159 |
|---|---|
| Title | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies |
| Official title | Phase II Study of 852A Administered Subcutaneously in Patients With Hematologic Malignancies Not Responding to Standard Treatment |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | 852A |
| Enrollment | 6 |
| Start date | Jan 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jan 13, 2006 |
| Last update posted | Sep 4, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: